Saxena, Nibha
Saxena, Nibha was paid $1.97M by Medicaid between Jan 2018 and Dec 2024, across 155 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 17% of everything it billed.
OAKWOOD VILLAGE, OH 44146
Next to other Anatomic Pathology & Clinical Pathology Physician providers in Ohio
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Paid by month
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 28,564 | $202K | |
| 2019 | 43,145 | $254K | |
| 2020 | 34,692 | $232K | |
| 2021 | 33,984 | $411K | |
| 2022 | 29,768 | $297K | |
| 2023 | 32,527 | $289K | |
| 2024incomplete | 49,397 | $284K |
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 17% | 5,812 | 4,818 | $326K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 6.7% | 3,012 | 2,846 | $132K |
| 80053 | Comprehensive metabolic panel | 6.4% | 24,233 | 18,895 | $125K |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | 4.9% | 403 | 395 | $96K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 4.7% | 31,597 | 22,022 | $93K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 4.5% | 4,109 | 3,865 | $90K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 4.5% | 4,108 | 3,865 | $89K |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 3.7% | 1,559 | 1,425 | $74K |
| 84443 | Thyroid stimulating hormone (TSH) | 2.5% | 6,189 | 5,793 | $49K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 2.3% | 1,894 | 1,607 | $45K |
| 87086 | Culture, bacterial; quantitative colony count, urine | 2.0% | 7,668 | 6,966 | $39K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | 1.9% | 499 | 436 | $38K |
143 more codes
| 80048 | Basic metabolic panel (calcium, ionized) | 1.7% | 8,013 | $34K |
| 87480 | 1.7% | 2,614 | $33K | |
| 87510 | 1.7% | 2,609 | $33K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 1.6% | 847 | $32K |
| 82803 | 1.5% | 2,682 | $29K | |
| 83735 | 1.4% | 7,596 | $27K | |
| 87040 | 1.2% | 2,418 | $23K | |
| 87660 | 1.1% | 2,761 | $22K | |
| 83605 | 1.1% | 3,965 | $22K | |
| 87641 | 1.1% | 982 | $22K | |
| 88342 | 1.1% | 1,404 | $22K | |
| 82962 | <1% | 10,789 | $20K | |
| 82330 | <1% | 2,072 | $18K | |
| 87081 | <1% | 5,864 | $17K | |
| 84484 | <1% | 3,176 | $16K | |
| 80061 | Lipid panel | <1% | 4,301 | $14K |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | <1% | 987 | $14K |
| 87186 | <1% | 2,388 | $13K | |
| 85730 | <1% | 2,881 | $13K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 1,698 | $12K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | <1% | 216 | $12K |
| 85610 | <1% | 5,223 | $11K | |
| 86780 | <1% | 1,303 | $11K | |
| 83880 | <1% | 1,036 | $11K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 813 | $10K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 3,230 | $10K |
| 83690 | <1% | 2,825 | $10K | |
| 86850 | <1% | 3,073 | $9K | |
| 81001 | <1% | 5,514 | $9K | |
| 80069 | <1% | 1,995 | $8K | |
| 84100 | <1% | 3,485 | $8K | |
| 81025 | <1% | 3,783 | $8K | |
| 86901 | <1% | 3,291 | $8K | |
| 84439 | <1% | 1,698 | $7K | |
| 82607 | <1% | 1,179 | $7K | |
| 86140 | <1% | 2,920 | $7K | |
| 86803 | <1% | 786 | $6K | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 242 | $6K |
| 80202 | <1% | 852 | $6K | |
| 86900 | <1% | 3,261 | $6K | |
| 87088 | <1% | 1,014 | $6K | |
| 82728 | <1% | 1,402 | $5K | |
| 87581 | <1% | 230 | $5K | |
| 84466 | <1% | 1,225 | $5K | |
| 85384 | <1% | 1,577 | $5K | |
| 87486 | <1% | 216 | $5K | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | <1% | 220 | $5K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 233 | $5K |
| 87340 | <1% | 679 | $4K | |
| 82784 | <1% | 632 | $4K | |
| 87147 | <1% | 2,501 | $4K | |
| 88307 | <1% | 82 | $4K | |
| 82570 | <1% | 1,749 | $4K | |
| 82805 | <1% | 204 | $4K | |
| 84702 | <1% | 907 | $4K | |
| 87070 | <1% | 1,310 | $4K | |
| 85027 | <1% | 1,335 | $4K | |
| 81003 | <1% | 3,384 | $4K | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 485 | $4K |
| 85379 | <1% | 982 | $4K | |
| 83540 | <1% | 1,136 | $3K | |
| 83970 | <1% | 228 | $3K | |
| 82746 | <1% | 580 | $3K | |
| 86038 | <1% | 426 | $3K | |
| 82550 | <1% | 1,007 | $3K | |
| 83615 | <1% | 1,052 | $3K | |
| 85014 | <1% | 2,280 | $3K | |
| 87493 | <1% | 123 | $3K | |
| 83516 | <1% | 450 | $3K | |
| 80047 | <1% | 535 | $2K | |
| 85652 | <1% | 1,736 | $2K | |
| 87077 | <1% | 567 | $2K | |
| 86920 | <1% | 455 | $2K | |
| 88304 | <1% | 111 | $2K | |
| 87205 | <1% | 929 | $2K | |
| 84703 | <1% | 500 | $2K | |
| 82043 | <1% | 911 | $2K | |
| 87536 | <1% | 39 | $2K | |
| 82565 | <1% | 721 | $2K | |
| 86003 | <1% | 63 | $2K | |
| 84295 | <1% | 647 | $1K | |
| 84550 | <1% | 668 | $1K | |
| 84478 | <1% | 578 | $1K | |
| 86762 | <1% | 292 | $1K | |
| 85018 | <1% | 1,245 | $1K | |
| 84132 | <1% | 602 | $1K | |
| 82248 | <1% | 525 | $1K | |
| 82947 | <1% | 505 | $1K | |
| 83655 | <1% | 185 | $1K | |
| 80076 | <1% | 285 | $988.14 | |
| G0103 | Prostate cancer screening; prostate specific antigen test (psa) | <1% | 111 | $972.40 |
| 82247 | <1% | 409 | $940.65 | |
| 80074 | <1% | 51 | $935.60 | |
| 84145 | <1% | 78 | $928.60 | |
| 87075 | <1% | 141 | $915.22 | |
| 84481 | <1% | 193 | $903.57 | |
| 84156 | <1% | 731 | $850.05 | |
| 85045 | <1% | 646 | $810.16 | |
| 87505 | <1% | 15 | $793.05 | |
| 86706 | <1% | 114 | $724.54 | |
| 82951 | <1% | 98 | $620.47 | |
| 87807 | <1% | 104 | $590.43 | |
| 82785 | <1% | 128 | $569.03 | |
| 84403 | <1% | 46 | $537.20 | |
| 85576 | <1% | 34 | $507.96 | |
| 87899 | <1% | 48 | $480.40 | |
| 80050 | General health panel | <1% | 30 | $465.00 |
| 80164 | <1% | 94 | $432.66 | |
| 82140 | <1% | 98 | $423.41 | |
| 84146 | <1% | 62 | $376.95 | |
| 86480 | <1% | 15 | $363.93 | |
| 88141 | <1% | 45 | $330.80 | |
| 80177 | <1% | 67 | $300.22 | |
| 87427 | <1% | 46 | $285.46 | |
| 87045 | <1% | 45 | $269.26 | |
| 85347 | <1% | 92 | $264.74 | |
| 86431 | <1% | 55 | $205.42 | |
| 85049 | <1% | 141 | $194.63 | |
| 86880 | <1% | 51 | $166.15 | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 14 | $165.14 |
| 86376 | <1% | 41 | $160.32 | |
| 86308 | <1% | 62 | $146.75 | |
| 86359 | <1% | 25 | $143.92 | |
| 84480 | <1% | 34 | $136.32 | |
| 82670 | <1% | 14 | $112.47 | |
| 88313 | <1% | 15 | $109.65 | |
| 83020 | <1% | 15 | $107.75 | |
| 82272 | <1% | 98 | $105.82 | |
| 80306 | <1% | 16 | $95.81 | |
| 82950 | <1% | 33 | $76.89 | |
| 89051 | <1% | 26 | $76.70 | |
| 81015 | <1% | 72 | $75.82 | |
| 82274 | <1% | 13 | $74.22 | |
| 87046 | <1% | 49 | $65.56 | |
| 86360 | <1% | 13 | $63.05 | |
| 82150 | <1% | 16 | $62.11 | |
| 87102 | <1% | 13 | $55.80 | |
| 87184 | <1% | 12 | $43.01 | |
| 82009 | <1% | 36 | $41.88 | |
| 84300 | <1% | 16 | $38.16 | |
| 83050 | <1% | 22 | $33.00 | |
| 86592 | <1% | 17 | $29.00 | |
| 84157 | <1% | 14 | $16.80 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.